BioNTech SE (BNTX) Stock Analysis
Momentum Cont setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $104.34: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: Below-average business quality.
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial,... Read more
Sell if holding. Engine safety override at $104.34: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: Below-average business quality. Chart setup: Trend continuation, RSI 65, MACD bullish. Score 4.0/10, high confidence.
Passes 5/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.60, semi cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Revenue shrinking — -23.7% YoY. Growth thesis broken unless recovery story develops.static
Unprofitable operations — net margin -39.6%. Quality floor flags this regardless of sector context.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $104.34: Quality below floor (2.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: Below-average business quality. Chart setup: Trend continuation, RSI 65, MACD bullish. Prior stop was $96.97. Score 4.0/10, high confidence.
Take-profit target: $117.35 (+12.5% upside). Prior stop was $96.97. Stop-loss: $96.97.
Quality below floor (2.8 < 4.0).
BioNTech SE trades at a P/E of N/A (forward -22.7). TrendMatrix value score: 5.3/10. Verdict: Sell.
27 analysts cover BNTX with a consensus score of 4.0/5. Average price target: $130.
What does BioNTech SE do?BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in...
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.